在COVID-19疫苗接种后,与贝赫特病相关的帕努韦炎:一个病例报告
Rou-Ting Lin1,2, Pei-Kang Liu3,4, Chia-Wei Chang2
1School of Medicine, College of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.
World journal of radiology
|October 2, 2024
概括
本案例研究报告了一种罕见的贝赫特病 (Behcet's disease,BD) 发病例,具体来说是帕努韦炎,发生在mRNACOVID-19疫苗接种后. 及时的皮质类固醇治疗对这些眼部炎症症状证明是有效的.
科学领域:
- 眼科医生 眼科 眼科
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 贝赫特病 (Behcet's disease,简称BD) 是一种全身性炎症状况,其特征是口腔/生殖器和眼部炎症.
- 膜炎是一种严重的膜炎,是贝赫特病的不常见的初始表现.
研究的目的:
- 在接种COVID-19疫苗后报告一种罕见的贝赫特病病例,呈现为肺炎.
- 探索mRNA COVID-19疫苗与BD相关眼部炎症的发生之间的潜在关联.
主要方法:
- 一名30岁的男性患有帕努韦氏炎后mRNACOVID-19疫苗接种病例报告.
- 诊断工作包括排除感染,HLA-B51测试和病史的评估.
- 治疗涉及皮质类固醇用于复发的帕努韦炎发作.
主要成果:
- 患者在第一剂mRNACOVID-19疫苗接种后发病了松膜炎,诊断通过HLA-B51阳性和病史得到证实.
- 在接种第二剂疫苗后,发生了第二次帕努韦炎发作.
- 这两次发作都在皮质类固醇治疗后得到改善.
结论:
- 这一案例表明mRNACOVID-19疫苗接种与贝赫特病的发病之间存在潜在的,尽管很少见的联系,特别是像 panuveitis 这样的眼部表现.
- 强调在疫苗接种后出现泛膜炎的患者中考虑BD的重要性.
- 强调及时使用皮质类固醇治疗来管理BD相关的肺炎.
相关概念视频
01:28Angle Closure Glaucoma: Treatment
1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
01:01Hypersensitivity Reactions: Cytolytic Reactions
208
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
208
01:22Pericarditis I: Introduction
758
Pericarditis is defined as the inflammation of the pericardium, the thin, sac-like membrane surrounding the heart. This condition can cause significant chest pain and other symptoms, often necessitating medical intervention. The pericardium has two layers: the inner visceral layer and the outer parietal layer, separated by a small amount of fluid that reduces friction during heartbeats.Types of PericarditisPericarditis can be classified into several types based on the duration and nature of the...
758
01:17Pericarditis III: Medical Management
586
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
586
01:27Cytomegalovirus Disease
102
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
102
01:19Hypersensitivity Reactions: Immune-Complex Reactions
269
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
269